A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9–11 year-old girls and boys – clinical protocol

BACKGROUND: Human papillomavirus (HPV) vaccines are indicated for the prevention of cancers and genital warts caused by vaccine-covered HPV types. Although the standard regimen requires a two or three-dose vaccine series, there is emerging data suggesting that a single dose of the bivalent or quadri...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Yi, Moscicki, Anna-Barbara, Sahasrabuddhe, Vikrant V., Garcia, Francisco, Woo, Heide, Hsu, Chiu-Hsieh, Szabo, Eva, Dimond, Eileen, Vanzzini, Susan, Mondragon, Angelica, Butler, Valerie, DeRose, Hillary, Chow, H.-H. Sherry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444524/
https://www.ncbi.nlm.nih.gov/pubmed/30935375
http://dx.doi.org/10.1186/s12885-019-5444-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444524/
https://www.ncbi.nlm.nih.gov/pubmed/30935375
http://dx.doi.org/10.1186/s12885-019-5444-4

Ejemplares similares